RO7017773 first-in-human SAD/MAD placebo-controlled study in healthy adults

Phase 1, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing RO7017773 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events, Changes in vital signs, physical findings, ECG parameters, and clinical laboratory results and 1 more. Started Dec 2017; status: active, not recruiting.